Metabolic Patterns of Fentanyl, Meperidine, Methylphenidate, Tapentadol and Tramadol Observed in Urine, Serum or Plasma
Open Access
- 23 January 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 41 (4) , 289-299
Abstract
Drug testing is a useful tool to identify drug use or monitor adherence to prescription drugs. The interpretation of drug results can be complicated based on the pattern and proportional concentrations of drugs and/or drug metabolite(s). The purpose of this retrospective study was to detect the positivity rates and metabolic patterns of five prescription drugs, including fentanyl, meperidine, methylphenidate, tapentadol and tramadol. Retrospective data were retrieved from the laboratory information system in a national reference laboratory. Drug testing was performed using four mass spectrometry methods that were validated for clinical use. For urine specimens, the positivity rate was the highest for methylphenidate (62.3%, n = 2,489), followed by tramadol (43.7%, n = 3,483), fentanyl (41.9%, n = 4,657), tapentadol (37.9%, n = 736) and meperidine (8.3%, n = 138). Among positive samples, both parent drug and metabolite(s) was detectable in 94.9% of meperidine samples, 94.5% of tramadol samples, 93.8% of fentanyl samples, 89.9% of methylphenidate and 86.6% of tapentadol samples. For serum or plasma specimens, the positivity rate was the highest for tapentadol (75.0%, n = 39), followed by methylphenidate (74.2%, n = 569), fentanyl (53.6%, n = 113), meperidine (41.9%, n = 18) and tramadol (28.9%, n = 213). Similar metabolic patterns were found in serum or plasma. Of positive results, both parent drug and metabolite(s) were found in 94.7% of fentanyl samples, 83.3% of meperidine samples, 79.6% of methylphenidate samples, 53.8% of tapentadol samples and 44.1% of tramadol samples. Our data demonstrates the metabolic patterns of five drugs from a random urine or serum/plasma collection in patients that have been prescribed these medications. The data presented can be used to guide clinicians in determining drug adherence by assessing the positivity rates of the parent drug and corresponding metabolite(s).Keywords
Funding Information
- ARUP Institute for Clinical and Experimental Pathology
This publication has 39 references indexed in Scilit:
- Guidelines for Field Triage of Injured PatientsWestern Journal of Emergency Medicine, 2013
- Commonly prescribed medications and potential false-positive urine drug screensAmerican Journal of Health-System Pharmacy, 2010
- Liquid Chromatography–Tandem Mass Spectrometry Assay for Androstenedione, Dehydroepiandrosterone, and Testosterone with Pediatric and Adult Reference IntervalsClinical Chemistry, 2010
- In vitro and in vivo characterization of tapentadol metabolitesMethods and Findings in Experimental and Clinical Pharmacology, 2010
- Effects of Application to Two Different Skin Sites on the Pharmacokinetics of Transdermal Methylphenidate in Pediatric Patients with Attention-Deficit/Hyperactivity DisorderJournal of Child and Adolescent Psychopharmacology, 2009
- Urine drug testing in pain medicineJournal of Pain and Symptom Management, 2004
- Development and validation of a gas chromatography-mass spectrometry assay for hair analysis of amphetamine, methamphetamine and methylenedioxy derivativesJournal of Chromatography B, 2003
- EVALUATION OF MITRAL VALVE OPERATIONS USING INTRAOPERATIVE 2-D CONTRAST ECHOCARDIOGRAPHY(2DCE)Anesthesiology, 1984
- The determination of meperidine, noremeperidine and deuterated analogs in blood and plasma by gas chromatography mass spectrometry selected ion monitoringJournal of Mass Spectrometry, 1980
- Investigation of the urinary excretion of pethidine and five of its metabolites in man using selected ion monitoringJournal of Mass Spectrometry, 1980